TABLE 2.
Plasmids used in this study
| Plasmid | Relevant featuresa | Source or reference |
|---|---|---|
| pRY111 | PCc-cat mobIncP oriVpIP1455 oriVpBR322 | 75 |
| pRYGG1 | PsapA in the pRY111 MCS | 33 |
| pRYSS1 | Fusion (Φ) (PsapA-aphA-3) in pRYGG1 | 33 |
| pRYVL1 | Φ(PsapA-aphA-3) in pRYGG1; BamHI and PstI linker inserted between PsapA and aphA-3 | 33 |
| pRYVL2 | Φ(PsapA-virD4-aphA-3) in pRYGG1 | 33 |
| pRYMJ2 | Φ(PsapA-Cfv-virB9-virB10-virB11-virD4) in pRYGG1 | 33 |
| pRYEL1 | Φ(PsapA-gfp) in pRYGG1 | 33 |
| pSK108-1 | 3,207 bp of pCFV108 in pBluescript KS II(−) | 33 |
| pRYSK2 | oriVpIP1455 replaced by oriVpCFV108 | 33 |
| pBlue-oriT | mobIncP in the pBluescript KS II(−) MCS | 33 |
| pRYSK3 | pCFV108 iterons; Φ(PsapA-aphA-3) in pBlue-oriT | 33 |
| pRYSK9 | mobApCfv108 in pRYSK3 | This study |
| pRYSK17 | nicpIP1455 in pRYSK3 | This study |
| pRYBM5 | Φ(PgatC-aphA-3); PsapA of pRYVL1 replaced by PgatC | This study |
| pRYSK12 | Φ(PgatC-virD4); PsapA of pRYVL2 replaced by PgatC | This study |
| CFP B | Cre fusion plasmid | 49 |
| pCreSK1 | Φ(Cre-fic1) in CFPB | This study |
| pCreSK2 | Φ(Cre-fic2) in CFPB | This study |
| pRYSK13 | Φ(Cre-fic1) in pRYSK3 | This study |
| pRYSK14 | Φ(Cre-fic2) in pRYSK3 | This study |
| pRYSK15 | Cre in pRYSK3 | This study |
| pCreTraI R1 | R1 traI encoding residues 3 to 1756 in CFP B | 39 |
| pCreTraI F | KpnI-SalI traI fragment from p99I+ in CFP B | 39 |
| pSU1501 | R388 trwC in pKK223-3 | 29 |
| pCreTrwC | R388 trwC encoding residues 2 to 966 in CFP B | This study |
| pJMTraD | Wild-type F traD in pBAD24 | 42 |
| pKD46 | Red recombinase expression plasmid: araBp gam-bet-exo oriR101 repA101(Ts) bla | 17 |
| RP4 | IncP conjugative plasmid | 48 |
| pSU2007 | IncW conjugative plasmid; Kmr | 44 |
| pAR119 | IncF conjugative plasmid; Kmr | 52 |
| pLG211 | IncI conjugative plasmid; Kmr | 14 |
| R1-16 | IncFII conjugative plasmid; Kmr fin- | 27 |
| pOX38 | IncFI, conjugative plasmid, KmR | 13 |
| pOX38traD411 | traD-null derivative of pOX38 | 43 |
a
Kmr, kanamycin resistance.